SCHEMBL2341103

SCHEMBL2341103

CC(C)(C)[C@H](Nc1cc(F)cc(OC(F)(F)F)c1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.38
EPHX2 P34913 1/20 0.35
FFAR4 Q5NUL3 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
WDR5 P61964 1/20 0.34
BRAF P15056 1/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
SCN8A Q9UQD0 2/20 0.33
SCN10A Q9Y5Y9 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327182 0.86 HPGD (0.34) PPARAEPHX2TRPV1NPC1RAB9A
SCHEMBL2339653 0.81 LMNA (0.49) EPHX2NPC1RAB9AALDH1A1HPGD
SCHEMBL1636008 0.79 HDAC3 (0.41) ALDH1A1LMNA
SCHEMBL1636010 0.79 HDAC3 (0.41) ALDH1A1LMNA
SCHEMBL23213602 0.75 EPHX2 (0.45) PPARAEPHX2FFAR4TRPV1NPC1
SCHEMBL2220603 0.75 MEN1 (0.45) NPC1RAB9AALDH1A1LMNAPOLB
SCHEMBL2220609 0.75 MEN1 (0.45) NPC1RAB9AALDH1A1LMNAPOLB
SCHEMBL3042876 0.73 MMP2 (0.50) NPC1RAB9AALDH1A1HPGDPOLB
SCHEMBL13224065 0.73 MMP2 (0.50) NPC1RAB9AALDH1A1HPGDPOLB
SCHEMBL30781021 0.71 RORC (0.46) EPHX2NPC1RAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358736-A1 THERAPEUTIC ANTIVIRAL PEPTIDES Intermune, Inc. (US) 2011-08-24 EP disclosed
US-20100119479-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-05-13 US disclosed
US-20100119479-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-05-13 US disclosed
US-20100119479-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-05-13 US disclosed
WO-2010045266-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-04-22 WO disclosed
WO-2010045266-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119479-A1 THERAPEUTIC ANTIVIRAL PEPTIDES SARS1, VIP, MAVS PPARA 2099/4885EPHX2 4366/4885FFAR4 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.